Table 1.

Prevalence of chlamydia-reactive antibody determined by MIF assay and rDNA LPS ELISA

Study populationNo. of subjectsPrevalence (%) observed by the following:rDNA LPS ELISAa
MIF assayrDNA LPS ELISASensitivity (%)Specificity (%)NPV (%)PPV (%)
Blood donors1,10471.229.433.580.532.980.9
COPD patients27172.053.1b 64.175.044.986.8
  • a The MIF assay was used as the gold standard.

  • b P < 0.0001 compared to blood donors.